Total 25(OH) Vitamin D, Free 25(OH) Vitamin D and Markers of Bone Turnover in Cirrhotics with and Without Synthetic Dysfunction

Overview

Journal Liver Int

Specialty Gastroenterology

Date 2015 Mar 12

PMID 25757956

Citations 23

Authors

Jennifer C Lai

Daniel D Bikle

Blanca Lizaola

Hilary Hayssen

Norah A Terrault

Janice B Schwartz

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Current clinical assays for total 25-hydroxy (OH) vitamin D measure vitamin D bound to vitamin D-binding protein (DBP) and albumin plus unbound ('free') D. We investigated the relationship between total and free 25(OH)D with bone metabolism markers in normal (>3.5 g/dl) vs. low (≤3.5 g/dl) albumin cirrhotics.

Methods: Eighty-two cirrhotics underwent measurement of free and total 25(OH)D by immunoassay, DBP and markers of bone metabolism [intact parathyroid hormone (iPTH), C-telopeptide (CTX), bone-specific alkaline phosphatase (BSAP), osteocalcin, amino-terminal pro-peptide of type 1-collagen (P1NP)]. Pearson's coefficients assessed relevant associations.

Results: Cirrhotics with low (n = 54) vs. normal (n = 28) albumin had lower total 25(OH)D (12.1 vs. 21.7 ng/ml), free 25(OH)D (6.2vs.8.6 pg/ml) and DBP(91.4 vs. 140.3 μg/ml) [P < 0.01 for each]. iPTH was similar in low and normal albumin groups (33 vs. 28 pg/ml; P = 0.38), although serum CTX(0.46vs.0.28 ng/ml) and BSAP(31.7 vs. 24.8 μg/L) were increased (P < 0.01). An inverse relationship was observed between total 25(OH)D and iPTH in normal (r = -0.47, P = 0.01) but not low albumin cirrhotics (r = 0.07, P = 0.62). Similar associations were seen between free 25(OH)D and iPTH(Normal: r = -0.46, P = 0.01; Low: r = -0.03, P = 0.84). BSAP, osteocalcin and P1NP were elevated above the normal range in all cirrhotics but not consistently associated with total or free 25(OH)D.

Conclusions: Cirrhotics with low vs. normal albumin have lower levels of DBP, total and free 25(OH)D. The expected relationship between total or free 25(OH)D with iPTH was observed in normal but not in low albumin cirrhotics, demonstrating that total 25(OH)D is not an accurate marker of bioactive vitamin D status in cirrhotics with synthetic dysfunction. Additional investigation into the role of vitamin D supplementation and its impact on bone mineral homoeostasis in this population is needed.

Citing Articles

Effect of hypoalbuminemia on drug pharmacokinetics.

Idasiak-Piechocka I, Lewandowski D, Swigut W, Kalinowski J, Mikosza K, Suchowiejski P Front Pharmacol. 2025; 16:1546465.

PMID: 40051558 PMC: 11882431. DOI: 10.3389/fphar.2025.1546465.

The Causal Relationship between PCSK9 Inhibitors and Osteoporosis Based on Drug-Targeted Mendelian Combined Mediation Analysis.

Zhang N, Ji C, Liu L, Ye E, Yuan C Calcif Tissue Int. 2024; 115(1):53-62.

PMID: 38789568 PMC: 11153280. DOI: 10.1007/s00223-024-01228-x.

Investigation of the influential factors for hepatic osteodystrophy in chronic liver disease: A case-control survey among the patients attending a tertiary care hospital in a rural region of Northern India.

Yadav E, Kaur R, Sasan A, Garg S Tzu Chi Med J. 2023; 35(1):95-102.

PMID: 36866351 PMC: 9972938. DOI: 10.4103/tcmj.tcmj_27_22.

Association between osteoporosis and hepatitis B cirrhosis: a case-control study.

Zhang Y, Gao X, Liu T, Gao P, Li H, Liu N Afr Health Sci. 2021; 20(4):1610-1616.

PMID: 34394221 PMC: 8351827. DOI: 10.4314/ahs.v20i4.13.

The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status.

Bikle D JBMR Plus. 2021; 5(1):e10418.

PMID: 33553985 PMC: 7839820. DOI: 10.1002/jbm4.10418.

References

Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View

Malham M, Jorgensen S, Ott P, Agnholt J, Vilstrup H, Borre M . Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology. World J Gastroenterol. 2011; 17(7):922-5. PMC: 3051142. DOI: 10.3748/wjg.v17.i7.922. View

Matloff D, KAPLAN M, Neer R, Goldberg M, Bitman W, WOLFE H . Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology. 1982; 83(1 Pt 1):97-102. View

. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology. 2003; 125(3):937-40. DOI: 10.1016/s0016-5085(03)01060-6. View

Schwartz J, Lai J, Lizaola B, Kane L, Markova S, Weyland P . A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations. J Clin Endocrinol Metab. 2014; 99(5):1631-7. PMC: 4010704. DOI: 10.1210/jc.2013-3874. View

Collier J . Bone disorders in chronic liver disease. Hepatology. 2007; 46(4):1271-8. DOI: 10.1002/hep.21852. View

Fisher L, Fisher A . Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol. 2007; 5(4):513-20. DOI: 10.1016/j.cgh.2006.10.015. View

Lim L, Chalasani N . Vitamin d deficiency in patients with chronic liver disease and cirrhosis. Curr Gastroenterol Rep. 2011; 14(1):67-73. DOI: 10.1007/s11894-011-0231-7. View

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

10.

Bikle D, Gee E . Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes. Endocrinology. 1989; 124(2):649-54. DOI: 10.1210/endo-124-2-649. View

11.

Thomas M, Lloyd-Jones D, Thadhani R, Shaw A, Deraska D, Kitch B . Hypovitaminosis D in medical inpatients. N Engl J Med. 1998; 338(12):777-83. DOI: 10.1056/NEJM199803193381201. View

12.

Carey E, Balan V, Kremers W, Eileen Hay J . Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl. 2003; 9(11):1166-73. DOI: 10.1053/jlts.2003.50242. View

13.

Hepner G, Roginsky M, Moo H . Abnormal vitamin D metabolism in patients with cirrhosis. Am J Dig Dis. 1976; 21(7):527-32. DOI: 10.1007/BF01464758. View

14.

Giouleme O, Vyzantiadis T, Nikolaidis N, Vasiliadis T, Papageorgiou A, Eugenidis N . Pathogenesis of osteoporosis in liver cirrhosis. Hepatogastroenterology. 2006; 53(72):938-43. View

15.

Crippin J, Jorgensen R, Dickson E, Lindor K . Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol. 1994; 89(1):47-50. View

16.

Guichelaar M, Malinchoc M, Sibonga J, Clarke B, Eileen Hay J . Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease. J Bone Miner Res. 2003; 18(12):2190-9. DOI: 10.1359/jbmr.2003.18.12.2190. View

17.

Gonzalez-Calvin J, Munoz-Torres M, Mundi J . Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998; 28(3):695-9. DOI: 10.1002/hep.510280315. View

18.

Arteh J, Narra S, Nair S . Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2009; 55(9):2624-8. DOI: 10.1007/s10620-009-1069-9. View

19.

Bikle D, Gee E, Halloran B, Kowalski M, Ryzen E, Haddad J . Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab. 1986; 63(4):954-9. DOI: 10.1210/jcem-63-4-954. View

20.

Miroliaee A, Nasiri-Toosi M, Khalilzadeh O, Esteghamati A, Abdollahi A, Mazloumi M . Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. Hepatol Int. 2010; 4(3):634-40. PMC: 2940008. DOI: 10.1007/s12072-010-9194-2. View